GWS
FHTX icon

Glassman Wealth Services’s Foghorn Therapeutics FHTX Stock Holding History

Glassman Wealth Services’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-53
Closed -$1K – 1776
2022
Q1 		$1K Buy
+53
New +$727 ﹤0.01% 1395

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Glassman Wealth Services's FHTX Position: Q2 2022 in Review

Glassman Wealth Services sold out of Foghorn Therapeutics (FHTX) in Q2 2022, closing a stake of 53 shares — an estimated $1K sold.

Glassman Wealth Services first reported a position in FHTX in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 60 funds tracked by Wall St. Rank hold FHTX as of Q2 2022.

  • Glassman Wealth Services reported no remaining Foghorn Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Glassman Wealth Services sold 53 Foghorn Therapeutics shares in Q2 2022, an estimated $1K.
  • Glassman Wealth Services first reported a position in Foghorn Therapeutics in Q1 2022 and held it in 1 quarter.
  • Glassman Wealth Services's Foghorn Therapeutics position peaked at $1K in Q1 2022.
  • 60 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2022.

Based on Glassman Wealth Services's 13F filing for Q2 2022, filed 4 Aug 2022.